

Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ

**Ref:** FOI-032026-002292

**Date:** 10.04.2026

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000.

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments? - **Yes**

Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli) - **3**
- Dostarlimab (Jemperli) + Chemotherapy - **0**
- Hormone therapy (Progesterone or Letrozole) - **4**
- Lenvatinib + Pembrolizumab (Keytruda + Lenvima) - **2**
- Pembrolizumab monotherapy (Keytruda) - **0**
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) - **6**
- Durvalumab with Platinum-based Chemotherapy - **0**
- Pembrolizumab with Platinum-based Chemotherapy - **2**
- Any other SACT - **0**
- If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with **Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy** for Endometrial Cancer - **0**

Q3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy? – **unable to run a report for this information**

Q4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

- Dostarlimab (Jemperli) + Chemotherapy - **0**
- Hormone therapy (Progesterone or Letrozole) - **0**
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) - **5**
- Durvalumab with Platinum-based Chemotherapy - **0**
- Pembrolizumab with Platinum-based Chemotherapy - **1**
- Any other SACT - **0**

- If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for first line Endometrial cancer - **0**

Q5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

**We currently have 1 study open to recruitment in this disease area**

**Short Title**

**Risk of cancer and hyperplasia in thickened endometrium without PMB**

**Full title**

**Risk of cancer and hyperplasia in thickened endometrium without postmenopausal bleeding: a prospective multicentre study**

**IRAS Number:347263**

**14 patients to date**

**Planned end of recruitment is 31/08/2026**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team  
The Dudley Group NHS Foundation Trust**